edoc-vmtest

Items where Author is "Schwenkglenks, M."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: Article
Number of items: 16.

Article

Schmutz, C. and Mäusezahl, D. and Bless, P. J. and Hatz, C. and Schwenkglenks, M. and Urbinello, D.. (2017) Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in Switzerland. Epidemiology and infection, 145 (4). pp. 627-641.

Matter-Walstra, K. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2015) Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons : SAKK 89/09. Oncology, 88 (1). pp. 18-27.

Schandelmaier, S. and Conen, K. and von Elm, E. and You, J. J. and Blümle, A. and Tomonaga, Y. and Saccilotto, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital of Basel and Switzerland., and Amstutz, A. and Bengough, T. and Meerpohl, J. J. and Stegert, M. and Olu, K. K. and Tikkinen, K. A. O. and Neumann, I. and Carrasco-Labra, A. and Faulhaber, M. and Mulla, S. M. and Mertz, D. and Akl, E. A. and Sun, X. and Bassler, D. and Busse, J. W. and Ferreira-González, I. and Lamontagne, F. and Nordmann, A. and Gloy, V. and Raatz, H. and Moja, L. and Rosenthal, R. and Ebrahim, S. and Vandvik, P. O. and Johnston, B. C. and Walter, M. A. and Burnand, B. and Schwenkglenks, M. and Hemkens, L. G. and Bucher, H. C. and Guyatt, G. H. and Briel, M. and Kasenda, B. and Disco study group, . (2015) Planning and reporting of quality-of-life outcomes in cancer trials. Annals of Oncology, 26 (9). pp. 1966-1973.

Matter-Walstra, K. M. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Schwenkglenks, M. and Pestalozzi, B. C.. (2014) Delivery of health care at the end of life in cancer patients of four swiss cantons : a retrospective database study (SAKK 89/09). BMC cancer, Vol. 14. pp. 306-317.

Vulsteke, C. and Pfeil, A. M. and Schwenkglenks, M. and Pettengell, R. and Szucs, T. D. and Lambrechts, D. and Peeters, M. and van Dam, P. and Dieudonné, A. S. and Hatse, S. and Neven, P. and Paridaens, R. and Wildiers, H.. (2014) Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel. Breast cancer research and treatment, Vol. 147, H. 3. pp. 557-570.

Matter-Walstra, K. and Klingbiel, D. and Szucs, T. and Pestalozzi, B. C. and Schwenkglenks, M.. (2014) Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied? PharmacoEconomics, Vol. 32, no. 6. pp. 591-599.

Jürgens, V. and Ess, S. and Phuleria, H. C. and Früh, M. and Schwenkglenks, M. and Frick, H. and Cerny, T. and Vounatsou, P.. (2013) Tobacco-related cancer mortality : projections for different geographical regions in Switzerland. Swiss Medical Weekly, 143. w13771.

Joerger, M. and Matter-Walstra, K. and Früh, M. and Kühnel, U. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis. Annals of Oncology, Vol. 22, H. 3. pp. 567-574.

Pettengell, R. and Schwenkglenks, M. and Bacon, P. and Lawrinson, S. and Duehrsen, U.. (2011) Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma : results from an integrated analysis. Hematological oncology, Vol. 29, H. 4. pp. 177-184.

Szucs, T. D. and Blank, P. R. and Schwenkglenks, M. and Aapro, M.. (2011) Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology, 81 (1). pp. 45-49.

Matter-Walstra, K. W. and Dedes, K. J. and Schwenkglenks, M. and Brauchli, P. and Szucs, T. D. and Pestalozzi, B. C.. (2010) Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21 (11). pp. 2161-2168.

Blank, P. R. and Schwenkglenks, M. and Szucs, T. D.. (2009) Disparities in influenza vaccination coverage rates by target group in five European countries : trends over seven consecutive seasons. Infection, 37. pp. 390-400.

von Minckwitz, G. and Schwenkglenks, M. and Skacel, T. and Lyman, G. H. and Pousa, A. Lopez and Bacon, P. and Easton, V. and Aapro, M. S.. (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management : results from an integrated analysis. European journal of cancer, Vol. 45, H. 4. pp. 608-617.

McCann, S. and Schwenkglenks, M. and Bacon, P. and Einsele, H. and D'Addio, A. and Maertens, J. and Niederwieser, D. and Rabitsch, W. and Roosaar, A. and Ruutu, T. and Schouten, H. and Stone, R. and Vorkurka, S. and Quinn, B. and Blijlevens, N. and Ebmt Mucositis Advisory Group, . (2009) The Prospective Oral Mucositis Audit : relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone marrow transplantation, Vol. 43. pp. 141-147.

Pettengell, R. and Schwenkglenks, M. and Bosly, A.. (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Annals of hematology, Vol. 87, issue 5. pp. 429-430.

Matter-Walstra, KW. and Szucs, T. and Brauchli, P. and Schwenkglenks, M.. (2008) Randomisiert-kontrollierte Studien von Krebstherapien in der Schweiz. Outcomes Research und gesundheitsökonomische Aspekte. Schweizerische Ärztezeitung, 89 (36). pp. 1545-1549.

This list was generated on Sat Nov 23 04:49:46 2024 CET.